Short report

Peripheral neuropathy during long-term high-dose amiodarone therapy

AG FRASER, INF McQUEEN, AH WATT, MR STEPHENS
From the Departments of Cardiology and Neurology, University Hospital of Wales, Cardiff, UK

Summary Three patients developed peripheral neuropathy after taking amiodarone for more than 18 months. All had high serum concentrations of amiodarone and its desethyl metabolite; in one patient concentrations in a sural nerve biopsy were 80 times higher than in serum. Peripheral neuropathy is a complication of large doses of amiodarone taken over long periods.

The antiarrhythmic drug amiodarone was first reported as a cause of peripheral neuropathy in 1974. Subsequent authors have confirmed this association but they have not explained why particular patients develop this adverse effect. We report three patients who developed peripheral neuropathy while taking amiodarone. Drug concentrations were measured in serum and in one patient also in a peripheral nerve biopsy, and recovery was documented after withdrawal of amiodarone. Similar details have not been reported before. With information from previous reports, some factors can be identified which may be important in the genesis of amiodarone neuropathy.

Case reports

Patient 1
A 65-year-old lady presented in 1981 with paroxysmal atrial arrhythmias. She was given amiodarone 200 mg tid for 1 week, and thereafter 200 mg bd. Her arrhythmias were abolished but in September 1983 she reported progressive weakness of her legs over 6 months. She had become too weak to walk even with support, and had paraesthesiae in her arms and legs, numbness in her legs below the knees, and a tremor. On examination she had a distal symmetrical sensorimotor neuropathy with areflexia. Sensory nerve conduction studies (table) demonstrated reduced amplitude sensory nerve action potentials in the upper limbs, and absent sural nerve action potentials. Motor studies showed considerable slowing of maximum conduction velocity with marked dispersion in the median and ulnar nerves, while velocity could not be measured in the common peroneal nerve because extensor digitorum brevis was denervated. The results were compared with reference values quoted by Ma and Liveson. Two weeks after the amiodarone was stopped sural nerve biopsy was performed. The histological appearances were similar to previous reports of amiodarone neuropathy. Biochemical analysis by high performance liquid chromatography gave an amiodarone concentration in the nerve of 187 mg/kg wet weight, and a desethylamiodarone concentration of 203 mg/kg wet weight. At the same time serum concentrations were 2.3 and 2.6 mg/l respectively. Her symptoms started to improve soon after amiodarone was stopped, but no objective improvement was detected until 10 weeks later. After 4 months her paraesthesiae were greatly reduced in severity and muscle power had improved so that she could walk unaided. Knee jerks had returned but ankle jerks were still absent. After 9 months she had no sensory symptoms and muscle power was almost normal. Tests of motor nerve conduction confirmed a significant improvement.

Patient 2
This man with coronary artery disease presented in 1980 aged 73 yr with syncope caused by paroxysmal ventricular tachycardia. His arrhythmias were successfully controlled by amiodarone 200 mg daily but recurred after one year. He then took 600 mg daily for more than 2 years, followed by 400 mg daily for 2 months before the drug was discontinued. One year after starting amiodarone he reported a tremor, and 6 months later he reported unsteadiness when walking. Thereafter he developed progressive weakness of his arms and legs, dysaesthesiae in his hands and numbness in his legs. Treatment was continued until November 1983,
Peripheral neuropathy during longterm high dose amiodarone therapy

Table Details of amiodarone treatment, and results of nerve conduction tests.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Duration of treatment received study m</th>
<th>Total dose g</th>
<th>Serum concentrations</th>
<th>Sensory nerve action potentials</th>
<th>Motor Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Amiodarone mg/l</td>
<td>Desethyl amiodarone mg/l</td>
<td>Upper limb D2</td>
</tr>
<tr>
<td>1</td>
<td>26</td>
<td>321</td>
<td>3-1</td>
<td>2-3</td>
<td>3-7 A μV 3-5</td>
</tr>
<tr>
<td></td>
<td>21.11.83</td>
<td></td>
<td>3-1</td>
<td>2-3</td>
<td>3-7 A μV 3-5</td>
</tr>
<tr>
<td></td>
<td>14.12.83</td>
<td></td>
<td>3-1</td>
<td>2-3</td>
<td>3-7 A μV 3-5</td>
</tr>
<tr>
<td></td>
<td>20. 6.84</td>
<td></td>
<td>3-1</td>
<td>2-3</td>
<td>3-7 A μV 3-5</td>
</tr>
<tr>
<td></td>
<td>20. 10.83</td>
<td></td>
<td>3-1</td>
<td>2-3</td>
<td>3-7 A μV 3-5</td>
</tr>
<tr>
<td>2</td>
<td>42</td>
<td>505</td>
<td>2-3</td>
<td>2-3</td>
<td>2-6 A μV 3-5</td>
</tr>
<tr>
<td></td>
<td>24. 2.84</td>
<td></td>
<td>2-3</td>
<td>2-3</td>
<td>2-6 A μV 3-5</td>
</tr>
<tr>
<td>3</td>
<td>32</td>
<td>494</td>
<td>2-3</td>
<td>2-3</td>
<td>2-6 A μV 3-5</td>
</tr>
<tr>
<td></td>
<td>16. 8.83</td>
<td></td>
<td>2-3</td>
<td>2-3</td>
<td>2-6 A μV 3-5</td>
</tr>
<tr>
<td></td>
<td>11. 1.84</td>
<td></td>
<td>2-3</td>
<td>2-3</td>
<td>2-6 A μV 3-5</td>
</tr>
</tbody>
</table>

Abbreviations: TO Latency to negative take-off of action potential
A Amplitude of action potential
DL Distal latency
CV Conduction velocity
O No activity recorded
— Investigation not performed

when he was unable to stand properly and could walk slowly only with help. He had muscle wasting, severe weakness in his arms and legs, areflexia and sensory loss. Nerve conduction studies confirmed a severe mixed sensory and motor peripheral neuropathy (table). Three months after stopping amiodarone the symptoms had improved considerably. He felt that he could walk normally, but there had been no significant improvement in the results of nerve conduction tests. Motor studies demonstrated improved terminal latencies but no action potentials could be detected from the sural nerve.

**Patient 2**
A 50-year-old man with hypertensive heart disease was prescribed amiodarone in August 1980 for ventricular tachycardia. He took either 400 mg or 600 mg of amiodarone daily for almost 3 years. In March 1983 he complained of unsteadiness, tremor, paraesthesiae and numbness. He had burned his hand because of poor temperature sensation, but he had no muscle weakness and no other demonstrable sensory loss. Nerve conduction tests showed low amplitude sensory nerve action potentials, and reduced nerve conduction velocities (table). Amiodarone was stopped in July 1983 when the paraesthesiae became very troublesome. Six months later his sensory symptoms had almost completely resolved, and sensory nerve conduction showed a significant improvement.

**Discussion**
Two patients developed a severe sensorimotor neuropathy while taking amiodarone, and the third severe sensory symptoms with objective evidence of neuropathy. Other causes were excluded, and no patient was taking another drug reported to cause neuropathy. Nerve conduction studies suggested a chronic peripheral neuropathy with segmental demyelination. Our patients developed symptoms after taking amiodarone for 18, 19 and 30 months, compared with 24 months on average in the 20 patients previously reported.1-11 Their mean age was the same as in other reports (65 years). The average maintenance dose of amiodarone was similar; 533 mg/day in our patients compared with 505 mg/day in other series.1-11

Compared with a suggested therapeutic range for amiodarone of 1.0-2.5 mg/L,15 drug levels in our patients with neuropathy were high. The mean serum concentrations of amiodarone (2.4 mg/L) and desethylamiodarone (3.0 mg/L) were similar to two previous reports (amiodarone 2.4 and 5.0 mg/L, and desethylamiodarone 1.7 and 4.0 mg/L).10,11 Concentrations in the sural nerve biopsy were also high (about 80 times greater than in serum) and similar to the previous report of a forty fold increase in iodine content in an affected peripheral nerve.6 Drug concentrations in the sural nerve biopsy from our patient were higher than those found before in many other tissues at necropsy6 and in samples of sural nerve from two patients who died after taking 230 g of amiodarone over 19 months, and 240 g over 20 months (Drs D Holt and P Adams, personal communication). Neither had clinical evidence of neuropathy. Their sural nerve amiodarone concentrations were 70 and 43 mg/kg wet weight compared with 187 mg/kg in our patient, and the desethylamiodarone concentrations 69 and 116 mg/kg compared with 203 mg/kg. High serum concentrations of amiodarone and its metabolite are associated with peripheral neuropathy. Related high tissue concentrations may be the material factor. Although patients have developed neuropathy while taking a standard dose such as 200 mg/day7,10 they may nevertheless have had high serum and tissue concentrations. Amiodarone is variably absorbed and other authors have not related dosage to body.
weight or measured drug levels.

The mechanism of amiodarone neuropathy is unclear and may be non-specific. The desethyl metabolite is present in high concentrations in lysosomes especially in tissues rich in macrophages, and variable density inclusion bodies thought to be of lysosomal origin have been observed in the cytoplasm of Schwann cells in electron micrographs of affected nerves. These findings also suggest that the accumulation of high concentrations of amiodarone and its metabolite in peripheral nerves may produce neuropathy. Very similar microscopic appearances occur in the neuropathy induced by perhexilene maleate.

Severe peripheral neuropathy may not improve if treatment is discontinued. One patient who took amiodarone for 3 years after the onset of neurological symptoms showed no improvement when he died 3 months after the drug was stopped. Others have improved very little within the first few months of stopping amiodarone, but most patients reported previously have recovered slowly over 3–6 months. Occasionally recovery has been incomplete even after 5 years. The serial nerve conduction tests in our patients provide some objective confirmation of these reports, with no change apparent at 1–3 months but considerable improvement thereafter.

Our experience together with that in other published reports suggests that amiodarone neuropathy is usually an adverse effect of longterm treatment, associated with high drug concentrations. It may be more common in older patients, perhaps because of altered pharmacokinetics producing high tissue concentrations. Patients who take large doses of amiodarone for long periods should be monitored for the development of neuropathic symptoms or signs, because reduction of dose or withdrawal of treatment may be necessary to prevent significant morbidity.

We thank Drs LG Davies and K Evans for permission to report patients under their care, Dr R Weiser for his assistance, and Dr D Holt and Mr GCA Storey, Poisons Unit, Guy’s Hospital, London, for performing the amiodarone assays.

References